Dr. James Leslie
Karagianis
USMD
Zyprexa/Symbyax, Eli Lilly and Company
USA
Email:
karagianis_jamie@lilly.com
Qualifications
1985 M.D., Medical: Memorial University of
Newfoundland (MUN)
1983 B.S., Medical: Memorial University of
Newfoundland (MUN)
Publications
(Selected)
-
A
Holy Condition. Diagnosis, 1987;4(1):125.
-
A
Case of Tourette Syndrome Developing During Haloperidol Treatment. Canadian
Journal of Psychiatry, 1990;35(3):228-232.
-
Frequency
of Electroconvulsive Therapy Use at a Provincial Mental Hospital: A
Retrospective Study. Canadian Journal Of Psychiatry 1994;39:551-562.
-
Clozapine
- Associated Neuroleptic Malignant Syndrome: Two new cases and review of the
literature. Annals of Pharmacotherapy 1999;33:623-30.
-
Rapid
Tranquilization With Olanzapine in Acute Psychosis: A Case Series. J Clin
Psychiatry 2001;62(suppl 2):12-16.
-
High
Dose Olanzapine and Prolactin Levels. Karagianis J, Baksh A. Journal of Clinical Psychiatry 2003,
64(10):1192-1194.
-
Switching
Treatment-Resistant Patients with Schizophrenia or Schizoaffective Disorder to
Olanzapine: a one-year open label study with five–year follow-up. Karagianis J,
LeDrew K, Walker D. Current Medical Research and Opinion 2003, 19(6):473-480.
-
Case
Report: Edema Related to Olanzapine Therapy. Deshauer D, Erwin L, Karagianis J. Canadian Family Physician
2006;52:620-621.
-
Is
Hunger a Driver of the Cognitive Development? Treuer T, Karagianis J.
Neuropsychopharmacology 2006;31(10):2326-7.
-
What
Do We Know About Insulin Resistance and Glucose Metabolism in Patients with
Schizophrenia Treated with Antipsychotics? Karagianis J, Poole-Hoffman V,
Stauffer V, Treuer T. J Clin Psychiatry. 2007 May;68(5):799-800.
-
Reviewing
CATIE for Clinicians: Balancing Benefits and Risks Using Evidence Based
Medicine Tools. Karagianis J, Rosenbluth R, Tohen M, Ascher-Svanum H, Treuer T,
Silva de Lima M, Citrome L. Current Medical Research and Opinion 2007,
23(10):2551-7.
-
Risk
of treatment-emergent diabetes mellitus in patients receiving antipsychotics
Citrome L, Holt RIG, Zachry WM, Clewell JD, Orth PA, Karagianis J, Hoffmann
VP. Annals of Pharmacotherapy, 2007,
41(10): 1593-1603.
-
Parasitosis,
Dopaminergic Modulation and Metabolic Disturbances in Schizophrenia: Evolution
of a Hypothesis. Treuer T, Martenyi F, Karagianis J. Neuro Endocrinol Lett.
2007, Oct;28(5):535-40.
-
Can
Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis. Treuer
T, Karagianis J, Hoffmann VP. Invited Review for Current Molecular
Pharmacology. 2008, 1(3):270-272.
-
Orally
Disintegrating Psychotropics and Possible Impact on Weight. Karagianis J,
Poole-Hoffmann V, Arranz B, Treuer T, Maguire GA, de Haan L, Chawla B. Hum
Psychopharmacol. 2008 Jun;23(4):275-81.
-
Number
Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized Blinded
Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of
Schizophrenia. Stauffer V, Karagianis J, Sutton V, Ascher‑Svanum
H, Treuer T, Silva de Lima M, Ball T, Poole-Hoffmann V, Tohen M. Clinical
Schizophrenia and Related Psychoses, 2008 July:136-146.
-
Intramuscular
olanzapine versus short-acting typical intramuscular antipsychotics: Comparison
of real-life effectiveness in the treatment of agitation. Castle DJ, Udristoiu
T, Yoon Kim C, Sarosi A, Pidrman V, Omar AN, Rosales JI, Melamed Y, Isik T, Karagianis J, Treuer T.
World J Biol Psychiatry. 2009 Jan 9:43-53.
-
A
randomized controlled trial of the effect of sublingual orally disintegrating
olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study.
Karagianis J, Grossman L, Landry J, Reed V, de Haan L, Maguire GA, Hoffmann VP,
Milev R. Schizophrenia Research 2009;113:41-48.
-
Intramuscular
olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability
and the switch to oral antipsychotic medication in patients with schizophrenia
or acute mania. Chandrasena R, Dvořáková D, Lee SI, Loza N, Mosolov SN, Osváth
P, Pregelj P, Walton RJ, Karagianis J, Treuer T. Int J Clin Pract. 2009
Aug;63(8):1249-58. Epub 2009 Jun 24.
-
Antipsychotic
switching: results from a one-year prospective, observational study of patients
with schizophrenia. Karagianis J, Williams R, Davis L, Hanley JB, Chandrasena
R, Thakur A and Dickson R. Current Medical Research and Opinion 2009; 25
(9):2121-32.
-
Worldwide-Schizophrenia
Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional
observational data from more than 17,000 patients. Karagianis J, Novick D, Haro
JM, Dossenbach M, Montgomery W, Pecenak J, Treuer T, Walton R, Lowry A.
International Journal of Clinical Practice 2009;63(11):1578-88.
-
Changes
in Weight and Metabolic Parameters during treatment with Antipsychotics and
Metformin. Do the data inform as potential guideline development? A systematic
review of clinical studies. Bushe C, Bradley A, Doshi S, Karagianis J. Int J.
Clin. Pract. 2009 Dec;63(12):1743-61. Epub 2009 Oct 19.
-
Pharmacological
treatment outcomes in Latin American patients with bipolar I disorder.
Garcia-Bonetto G, Nieto I, Chapa R, Adrianzén C, Brnabic A, Meyers A, Granger R, Dossenbach M,
Karagianis J, Ruiz I. Archivos de Neurociencias Vol. 14 no. 4 octubre_diciembre
2009.
-
Number
Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar
Disorder. Tohen M, Sniadecki J, Sutton VK, Degenhardt EK, Karagianis JL, Sagman
D, Jacobson JG. Journal of Clinical Psychopharmacology 2009 Dec;29(6):520-8.
-
The
Number Needed to Treat for All-Cause Medication Discontinuation in the
Treatment of Schizophrenia: Consistency Across World Geographies and Study
Designs. D. Novick, H. Ascher-Svanum, B. Zhu, A. Brnabic, V. Stauffer, X. Peng,
J. Karagianis, E. Perrin. Pharmacopsychiatry 2010 May;43(3):81-5. Epub 2009 Dec
16.